Riskpilot← Back to searchSign inGet full accessKARDIOKONSULT AS
ASActiveOrg 957207529Vesterøyveien 48, 3235 SandefjordMedical specialists activities · NACE 8622Est. 19901 employeeswww.cardio.no
Revenue 2024
NOK 2,7M
+56% vs 2023
EBITDA margin
24.6%
+766% vs 2023
Equity ratio
92.5%
Financial strength
Net profit 2024
NOK 449K
+107% vs 2023
| Revenue | NOK 2,7M | +56% |
| EBITDA | NOK 660K | +766% |
| Net profit | NOK 449K | +107% |
| Total assets | NOK 4,3M | -5% |
| Equity | NOK 4M | -6% |
| Employees | 1 | — |
Legal name
KARDIOKONSULT AS
Org number
957207529
Legal form
Aksjeselskap
NACE code
8622 · Medical specialists activities
Founded
23. januar 1990
Share capital
NOK 100 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Company purpose
Drive spesialistlegepraksis, forskning relatert til hjerte-karsykdommer samt annen relevant næringsvirksomhet.
Address
Vesterøyveien 48, 3235 Sandefjord
Website
www.cardio.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 2 006 | 1 340 | 2 771 | 1 727 | 2 687 |
| Staff expenses | −5 | −13 | −38 | −301 | −213 |
| EBITDA | 1 454 | 150 | 975 | 76 | 660 |
| Depreciation & amort. | −0 | −52 | −138 | −138 | −81 |
| EBIT | 1 454 | 98 | 837 | −62 | 579 |
| Net financials | 86 | 206 | −132 | 296 | −6 |
| Profit before tax | 1 541 | 304 | 705 | 235 | 573 |
| Tax | 320 | 36 | 243 | 18 | 124 |
| Net profit | 1 221 | 268 | 463 | 216 | 449 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 4 237 | 4 153 | 4 586 | 4 509 | 4 286 |
| Equity | 3 670 | 3 938 | 4 201 | 4 217 | 3 966 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 393 | 76 | 231 | 191 | 266 |
| Total debt | 567 | 215 | 385 | 292 | 320 |
EBITDA margin
24.6%
This company
15.8%
Market median
+56% vs market
20202024
Equity ratio
92.5%
This company
38.2%
Market median
+142% vs market
20202024
Return on equity
11.3%
This company
18.4%
Market median
+39% vs market
20202024
Net profit margin
16.7%
This company
8.1%
Market median
+106% vs market
20202024
Asset turnover
0.63×
This company
1.12×
Market median
-44% vs market
20202024
Debt / equity
0.08×
This company
0.62×
Market median
+87% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
HK Deputy Member | Deputy Member | 2019 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2019 | |
| Board of Directors | 2019 | |
| Chairman | 2019 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of KARDIOKONSULT AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Helena Kristin Rønvik | Deputy Member | 0 companies |
| Heidi Elisabeth Granholt Sirnes | Board of Directors | 0 companies |
| Even Harry Rønvik | Board of Directors | 0 companies |
| Per Anton Sirnes | Chairman | 0 companies |